In a ruling handed down on October 18, 2025, the CJEU ruled in Case C-2/24 P, Teva v. Cephalon v. European Commission, clarifying the conditions under which an amicable settlement agreement between patent holders and generic manufacturers can be classified as an anti-competitive agreement.

In this article, Renaud Christol and Paul Vialard review the implications of this decision and the criteria used by the Court to assess the compliance of “pay for delay” agreements with competition law.

Download the PDF